ࡱ> 46123 mbjbj΀ >he7`C`CPPPPPPPP8PQ\PT(U")U)U)UVVV35555555P`VV``5PP)U)UJfff``P)UP)U3f`3ffD)U=!Pe<7&`0]BTNfTLTPVXfvZ|[VVV55fVVV````TVVVVVVVVV`C iO:  Maryland Board of Pharmacy Public Meeting MINUTES May 19, 2010 Todays Attendance Year-to-Date Attendance Name TitlePresentAbsent Present AbsentAnderson, C. CommissionerX101Bradley-Baker, L.CommissionerX110Chason, D.CommissionerX110Finke, H.Commissioner X101Handelman, M.Commissioner X101Israbian-Jamgochian, L.CommissionerX110Leandre, A. CommissionerX101Matens, R.CommissionerX92Souranis, M.Commissioner/TreasurerX92Taylor, D.Commissioner/PresidentX110Taylor, R.Commissioner/SecretaryX101Zimmer, R.CommissionerX101Bethman, L.Board CounselX110Gibbs, F.Board CounselX110  Banks, T.MIS Manager X65 Gaither, P. Administration and Public Support ManagerX110 Goodman, S.Licensing ManagerX74 Jeffers, A. Legislation/Regulations ManagerX110 Naesea, L.Executive DirectorX110Waddell, L. Executive Secretaryx92France, KCompliance Officerx21Seeds, JPIOX30 Subject Responsible Party DiscussionMotionACTION/RESULTSI. Call to Order & Approval of Minutes Donald Taylor, Board President A. D. Taylor called the Public Meeting to order at 9:00am. B. D. Taylor requested all meeting attendees to introduce themselves and to remember to sign the guest list before they leave the meeting. C. D. Taylor reported that guests will be given packets of materials so that they can follow meeting discussions. He requested that the guests please return the draft packets when they leave the meeting. D. Members of the Board with a conflict of interest relating to any item on the agenda were advised to notify the Board at this time or when the issue is addressed in the agenda. Introduction of pharmacy student on rotation with LaVerne Naesea at the Board: Mary Bales. E. Revisions to Minutes: Approval of April 21, 2009.  Motion to accept minutes as amended: R. Matens Second: R. Zimmer  Board Action: The voted to approve the minutes as amended. II. Meeting Updates  Donald Taylor, Board President A. Meeting Updates 1. R. Zimmer attended the ACPE Accreditation Review at the College of Notre Dame School of Pharmacy on April 27-29, 2010. He indicated that it was a very interesting and thorough process and that it appeared that the college would pass the second level of ACPE accreditation. 2. M. Handelman represented the Board at a meeting at OHCQ on bulk medications in Long Term Care on April 29, 2010. More information later. 3. L. Bradley-Baker attended the final APAP Coalition Meeting on May 12, 2010. Although the group will no longer meet, the Coalitions Facebook page will remain updated and active and any relevant information to the public regarding acetaminophen will be promoted through venues such as the Board of Pharmacys booth at the annual Baltimore City Flower Mart. 4. L. Bradley-Baker attended the Drug Therapy Management (DTM) Committee Meeting on May 12, 2010. The committee is currently reviewing the protocols from Peoples Community Center and the University Maryland, College Park. The Board of Physicians wanted the committee to omitted some information that it felt was not necessary under, though it is required under current DTM regulations. 5. L. Bradley-Baker attended the Maryland Pharmacy Coalition (MPC) meeting on May 13, 2010. The new chair of the MPC for the upcoming year is Chi Wang (University of Maryland School of Pharmacy Student Government). A review of the past legislative session as well as plans for the upcoming session was discussed. 6. R. Zimmer attended the Howard County CERN meeting on May 13, 2010. Discussions included: a. BRAC effort to expand Ft. Meade and NSA facilities; and b. Presentation by John Reginaldi about the Nuclear Detection Program 7. Home Infusion Workgroup met on May 5, 2010. Cindy Anderson indicated that the group should complete their charge within two more meetings. The next meeting will be held June 2, 2010. 8. Institutional Workgroup met on May 6, 2010. - Dave comments? 9. The Board Staff Retreat was held on May 17-18, 2010 at the Maritime Institute. 10. C. Anderson will be leaving tomorrow for a week working as a pharmacist in Haiti (from May 22-29, 2010). 11. The University of Maryland School of Pharmacy will hold their Honors Convocation ceremony on Friday May 21st at 9:30 am at the Sheraton Baltimore City Center Hotel. Don Taylor will present the Pharmacists Oath to the graduates. 12. NABP will hold its 106th Annual Meeting in Anaheim on May 22-25, 2010. L. Israbian-Jamgochian has been awarded a travel grant by NABP to represent the Board. Lenna asked the Boards opinion on a National License administered through NABP. The majority of Board members were not in favor of a national license. The concept of national standards for pharmacy technicians was also discussed. The majority of the Board members were in favor of this concept. 13. There will be a conference at the Baltimore Intercontinental Harbor Court June 28-29, 2010 titled Crossroads for Temperature Sensitive Drugs (USA). K. France, Pharmacist Compliance Officer, will be a panel speaker. The agenda is still in the planning stage, but the topic is timely from the Boards perspective. 14. The MPhAs annual conference will be held in Ocean City at the Clarion Resort Fountainebleau Hotel June 1215, 2010. The Board will host a booth at the event. 15. There will be a Summit for Healthcare Professionals held June 18, 2010 at the Turf Valley Resort in Ellicott City. The focus will be on Caring for Service Members, Veterans and Their Families. 16. There will be a MPVC training at BWI Weston on June 22, 2010 for all professional volunteers. 17. Deputy Secretary Frances Phillips has asked Don Taylor to participate in a Mid-Atlantic Region H1N1 Summit on June 24, 2010 at The Marriott Inn and Conference Center in Hyattsville, Maryland. Maryland, Virginia, and DC State Health Officers, their staffs and partners from the neighboring states of Pennsylvania, Delaware and West Virginia are invited. 18. National Conference on Quality Health Care for Culturally Diverse Populations will be held on Oct 18-21, 2010 at the Baltimore Renaissance Harborplace Hotel. L. Bradley-Baker will be attending to represent the Board. 19. NABP will be holding their District I and II Meeting in Cooperstown, NY October 29-31, 2010. B. Introduction of Guest Presenter, Dr. Jennifer Thomas, who is the Project Manager of the Delmarva Foundation (Pharmacy Quality Improvement Community - PQIC). Dr. Thomas gave an update on several medication safety projects. Two new potential areas of interest included oral anticoagulation and medication reconciliation.  III. Executive Director LaVerne Naesea, Executive Director A. Staffing Updates: With the recent permanent hirings of a Pharmacist Compliance Manager and Public Information Officer, the Board is fully staffed with the exception of one inspector. The freeze exemptions to hire a Help Desk and temporary employee for the Licensing Unit were approved and the two seniors aides appointed from the Baltimore City Health Department were all filled in May. B. Maryland Pharmacy Laws Book: The Board was requested to determine whether to continue amending to the State contract with Lexis/Nexis for the 2011 Lawbook or to consider issuing a bid in response to a request received from MPhA. C. Legislation Affecting Board Budget: HB 114 - L. Bethman reported that under HB 114, all Boards will be required to adopt sanctioning guidelines, in addition to other requirements. The A.Gs office is working on a framework and set of general recommendations to assist Boards in developing the guidelines. D.Receipt and Disposal of Prescription Medications----what was the issue discussed? E. Staff Retreat Summary: L. Naesea presented a summary of the staff training meeting. Overall, it was a successful program. F. Nomination of Board Officers: LaVerne will collect nominations for positions via email. Don recommended all Board members consider becoming an officer. Open nominations will be taken from the floor and the election conducted at the June 2010 board meeting. G. UKs Council for Healthcare Regulatory Excellence (CHRE) has requested that the Board become a member by filling out a survey. We would then have access to surveys filled out by other member nations (i.e., Australia, Canada, Denmark, Germany). B. Motion: D. Chason. Second: L. Israbian-Jamogchian D. Motion: D. Chason Second: H. Finke Motion: Second:  B. Board Action: The Board voted to continue with Lexis/Nexis contract. D. Board Action: Return letters to Practice Committee G. Board Action: No Action Will be presented to NABP by Lenna at the upcoming NABP meeting. IV. PEAC ReportKathy Putz, PEAC A. PEAC monthly statistics for the Board. See Attachment 1, Section D. V. Legislation and RgulationsAnna Jeffers, Legislation and Regulation Manager A. Maryland 1. Legislation: Bill Signing for HB 233 Physicians and Pharmacists Therapy Management Contracts Extension of Law, will be May 2008.2. Regulations - Status: 10.34.03 Inpatient Institutional Pharmacy To be presented at the May Practice Committee Meeting10.34.05, .07, .12, .13, and .15 Notice of Final Action published May 7, 2010 with an Effective Date of July 1, 2010. NoFA 10.34.05,.07,.12,.13&.15 Md R. 05071010.34.18 Continuing Education Notice of Final Action published May 7, 2010 with an Effective Date of July 1, 2010. NoFA 10.34.18 Md R 05071010.34.20.01 - .04 Format of Prescription Transmission Proposal anticipated to be published June 4, 201010.34.23 Pharmaceutical Services to Patients in Comprehensive Care Facilities Proposal anticipated to be published June 4, 2010 There was a brief discussion whether a Director of Pharmacy should be full time. The issue will be revisited when the Official Comments are considered10.34.25 Delivery of Prescriptions Proposal to be submitted to the Department of sign-off.10.34.28 Automated Medication Systems Published 12/04/10 Reproposal submitted to the Department April 12, 2010.10.13.01 Dispensing of Prescription Drugs by a Licensee Waiting to hear from Wendy Kronmiller LaVerne will make this a priority now that the staff training meeting is complete. Pharmacist non-CLIA testing No action, waiting on State laboratory to respond. VI. Inspection Program ReportKimberly France, Compliance OfficerA. Compliance monthly statistics for the Board. See Attachment 1, Section C. B. A Draft Quality Assurance Peer Review Proposal was reviewed by Cynthia Anderson. Refer to compliance for consideration on a case-by-case basis.  VII. Management Information Services  LaVerne Naesea A. MIS monthly statistics for the Board. See Attachment 1, Section F. MIS Updates- new help desk person has installed new printers and computers and performed other tasks as assigned. The MIS Manager is please with his performance. Proposal for database system The Board is awaiting an itemized bid from Systems Automation. VIII. Administration & Public SupportPatricia Gaither, Administration and Public Support ManageA. Administration and Public Support monthly statistics for the Board. See Attachment 1, Section G. B. Staffing Updates   IX. Public Relations Committee Report  Janet Seeds, Public Information Officer A. Public Relations Committee Report: J. Seeds reported that the Board of Pharmacy booth was the first place winner at the annual Baltimore City Flower Mart. It was a very successful event. She also thanked all the staff and Board members who attended and worked the booth at the event. B. Acetaminophen Coalition Report: The coalition is formally dissolved as it has completed all of its stated goals to educate the public on the safe use of acetaminophen. The coalition will reconvene if the need arises. C. DTM Committee report. Motion to send a letter to the Board of Physicians proposing to work together to revise the current DTM regulations. D. Boards Emergency Preparedness Committee will hold a training and update meeting on November 21, 2010 at the BWI Weston. Attendees would include current volunteers and pharmacists, pharmacy technicians and those pharmacists, pharmacy technicians and pharmacy students who wish to become volunteers.  C. Motion: Lynette Bradley-Baker Second: Dave Chason C. Board Action: The Board voted to approve the motion. X. Practice CommitteeReid Zimmer, Chair Anna Jeffers, Legislation and Regulation Manager Letter to DEA. 2. Practice Responses to Public Inquiries:a. Martha Russell, Cardinal Health;b. Marie Mason, Carolina Pharmaceuticals, Inc.c. Ron Keech, Village Green Apothecary Public Inquiries: 1) Jenny Harrison, Hills Pharmacy verbal inquiry. Response to Jenny Harrison-Pharm Techs-RxDrugRep Program A repository shall designate a pharmacist who shall: (1) Accept donated prescription drugs or medical supplies forwarded by: (a) A drop-off site; or (b) A manufacturer regulated by the U.S. Food and Drug Administration. (2) Inspect donated prescription drugs or medical supplies; (3) Accept donated prescription drugs or medical supplies that meet the requirements of Regulations .02 and .03 of this chapter; and (4) Obliterate from the labels of donated prescription drugs or medical supplies patient specific information for which the donated prescription drugs or medical supplies were originally dispensed when it is placed in inventory. See COMAR 10.34.33.06B. According to COMAR 10.34.33.05B, a pharmacist or health care practitioner accepting donated prescription drugs or medical supplies at a drop-off site may not delegate the initial step of acceptance of donated prescription drugs of medical supplies. A registered pharmacy technician employed at a drop-off site may be involved in the drop-off site process, after initial acceptance of the drugs by the pharmacist, in accordance with COMAR 10.34.33.07: A repository shall dispense donated prescription drugs or medical supplies in compliance with applicable federal and State laws and regulations for dispensing prescription drugs or medical supplies. 2) Jennifer Krusa, Omnicare Omnicare - expiration dates on labels Draft - Bd Response - Krusa Omnicare Dave Chason suggested amendments that are consistent with the following response: Thank you for contacting the Maryland Board of Pharmacy requesting clarification regarding expiration date labeling requirements on pharmacy prescription labels and "responsible pharmacist" duties of a Maryland licensed pharmacy. Below you will find responses to your inquiries. Expiration date of medications Omnicare Inc. asked if a pharmacy dispenses the manufacturer packaged or pharmacy repackaged medications, does the prescription label that is affixed to the manufacturer package or pharmacy repackaged product, require the expiration date to be printed directly onto the prescription label, or will wording on the prescription label, such as "Exp. date  see package" suffice in meeting the requirements for determining the accurate expiration date of the manufacturer packaged or pharmacy repackaged product. Wording on the prescription label, such as Exp. Date see package does not suffice in meeting the requirements for determining the accurate expiration date. The expiration date must appear on the prescription label. Responsible pharmacist duties Omnicare Inc. also requested clarification regarding the ability of a Maryland licensed pharmacist to be designated as the responsible pharmacist for more than one licensed pharmacy location in Maryland. In a full service pharmacy "a pharmacist shall be immediately available on the premises to provide pharmacy services at all times the pharmacy is in operation." See COMAR 10.34.05.03A. If a pharmacist is fulltime at one pharmacy, that pharmacist may not be listed as fulltime at another pharmacy at the same time. If the pharmacist is listed as parttime at two pharmacies then both pharmacies will have to list other pharmacists who will be working when the pharmacist in charge is not available. The hours of operation and the staffing of pharmacists must be consistent. Whether or not a director of pharmacy at a comprehensive care facility may be a director of pharmacy for more than one licensed pharmacy location at a time is not currently addressed in COMAR 10.34.23 Pharmaceutical Services to Residents in Long-Term Care Facilities. The Board is in the process of revising COMAR 10.34.23 and this issue will be addressed after the anticipated publication of those revisions in the Maryland Register on June 4, 2010. A 30 day comment period follows. Please refer to HYPERLINK "http://www.dsd.state.md.us"www.dsd.state.md.us and click on Maryland Register on the left menu. 3) Joanne Hawana,, Arent Fox Pedigree Question Private Label Distributors Draft - Bd Response - Hawana - Arent Fox The private label distributor you described in your e-mail would be required to be licensed as a wholesale distributor in Maryland because, as you indicated, it directs and controls the actual distribution of the product by the third-party logistics provider. Forms are available on the Boards website at: HYPERLINK "http://www.dhmh.maryland.gov/pharmacyboard"www.dhmh.maryland.gov/pharmacyboard Pursuant to our phone conversations, your next concern was how a private label distributor would affect the normal distribution channel and who would provide the pedigree. The definition of normal distribution channel is narrow and is provided below: (l)Normal distribution channel means a chain of custody for a prescription drug that, directly or by drop shipment, goes: (1)From: (i)A manufacturer of the prescription drug; or (ii)The manufacturers colicensed partner, third party logistics provider, or manufacturers exclusive distributor; and (2)To: (i)A pharmacy or other designated person authorized by law to dispense or administer the prescription drug to a patient; (ii)A wholesale distributor to a pharmacy or other designated person authorized by law to dispense or administer the prescription drug to a patient; (iii)A wholesale distributor to a pharmacy warehouse to the pharmacy warehouses intracompany pharmacy or other designated person authorized by law to dispense or administer the prescription drug to a patient; (iv)A pharmacy warehouse to the pharmacy warehouses intracompany pharmacy or other designated person authorized by law to dispense or administer the prescription drug to a patient; or (v)An authorized distributor of record to another authorized distributor of record solely for distribution to an officebased health care practitioner authorized by law to dispense or administer the prescription drug to a patient. Health Occupations Article, 12-6C-01, Annotated Code of Maryland The scenario described in your e-mail of April 1, 2010, is outside of the definition of normal distribution channel because the third party logistics provider distributes to other wholesale distributors, so it does not fall under 12-6C-01l(2)(v). Therefore, the private label distributor, of a prescription drug that leaves, or has ever left, the normal distribution channel shall provide, before each wholesale distribution of the prescription drugs, a pedigree to the person who receives the prescription drug. Health Occupations Article, 12-6C-10(a), Annotated Code of Maryland Since this is outside the normal distribution channel, the first authorized distributor of record would authenticate the pedigree as coming from the initial manufacturer. In your e-mail the first authorized distributor of record is the private label distributor who holds title to the product. 4) Doug Haggerty, Walgreens Haggarty - Schedule II prescription Draft - Bd Response - Haggerty Walgreens Returned to Practice Committee for further research and revisions. 5) Marianna F. Miyazaki, Arent Fox Vaccine distribution - Miyazaki - Arent Fox Draft - Bd Response - Miyazaki - Arent Fox Thank you for contacting the Maryland Board of Pharmacy concerning whether a company would need to be licensed by the Board if it purchases vaccines from a manufacturer/wholesale distributor for storage at one of the companys locations, and distributes to other of the companys locations, and then administered by a nurse pursuant to a physicians standing order. Please be advised that the company would have to be licensed as a wholesale distributor in Maryland in order for it to purchase vaccines and then distribute the vaccines to the physician/nurse. A nurse would administer the vaccines to individuals under the authority of the physicians license.  1. Motion: Practice Committee Second: Dave Chason 2. Motion: Dave Chason Second: Harry Finke 3. Motion: Practice Committee Second: Dave Chason 4. Motion: Practice Committee Second: Dave Chason 5. Motion: Practice Committee Second: Harry Finke  1. Board Action: The Board voted to approve the motion. 2. Board Action: The Board voted to return to practice 3. Board Action: The Board voted to approve the motion. 4. Board Action: The Board voted to return to Practice Committee 5. Board Action: The Board voted to approve the motion.XI. Licensing Committee Mike Souranis, Chair A. Licensing Committee statistics for the Board. See Attachment 1, Section A and E. B. Letter for Out-if-State Wholesale Drug or Device Distributor Renewals C. Approval of Repositories 1. Halethorpe Pharmacy 2. Joppa Road Pharmacy 3. Independent Pharmacy  B. Motion: Licensing Committee made a motion to approve letter. Second: Harry Finke C. Motion: Licensing Committee made a motion to approve all 3 Repository applicants, Second: Mayer Handelman  B. Board Action: The Board voted to approve the motion. C. Board Action: The Board voted to approve the motion.XII. Disciplinary CommitteeLenna Israbian-Jamgochian, Chair Compliance Committee monthly statistics for the Board. See Attachment 1, Section A and C. XIII. Long Term CareMayer Handelman, ChairCommittee Report Long Term Care letter should be drafted and sent to NABP for approval on controlled dangerous substance authority. Motion: Mayer Handelmann Second: Harry Finke Board Action: The Board voted to approve the motion.XIV. InformationalDonald Taylor, PresidentA. FDA has initiated a new program Bad Ad Program where they are asking physicians to report ads and sales pitches that violate FDA rules. They are also offering physicians training at medical conferences (providing funding). There is NO mention of pharmacist participation. B. Tennessee allows vending machines in medical clinics. One company is installing Rx vending machines that dispense 60 different generics and can hold 1000 Rxs. Patients are given an ID # and can just pick up their medications on exit. The company states that they are not cutting out pharmacists, but are only dealing with acute medications and not chronic medications. C. Pharmacists are increasingly finding a changed profession. Not only is the job market becoming wobbly, but the skill-set required has shifted. They now need to know how to work in different environments (retail clinics, mail-order businesses, nursing homes, consulting). They must also be comfortable with new technology, drug therapy management, changing issues/regulations related to Medicare/Medicaid and the new politics of health care reform. D. AMA Seeks Limits to Pharmacists Scope of Practice: 1. AMA is arguing that collaborative therapy has the potential to lead us to independent authority for pharmacists to monitor and modify medication therapy. 2. They have issued the AMA Scope of Practice Data Series: Compendium on Pharmacists which states among other things: a. Neither the Accreditation Council for Pharmacy Education nor state licensing requirements mandate direct patient contact for student practice experience, and b. No evidence exists that the profession has modified the quality or manner in which students are trained to provide direct care to patients. 3. AMA introduced HR 2260 that would have required all health care providers (other than medical doctors or doctors of osteopathic medicine) to issue disclaimers informing patients that they do not have the skills and training of MDs and DOs. That bill did not make it out of committee, but they are now introducing similar bills at the state level (3 billsat this point),A. Motion to send letter to FDA by Harry Finke Second: M. Souanis A. Board Action: The Board voted to approve the motion.XV. AdjournmentDonald Taylor, Board PresidentA. D. Taylor asked for a motion to close the Public Meeting and open a Closed Public Session for the purpose of engaging in medical review committee deliberations of confidential matters contained in technician applications in accordance with State Government, Sect. 10-508(a)(13).  Motion: Richard Matens Second: Dave Chason  The Public Meeting was adjourned at 11:48 am.      PAGE  PAGE 9 +@qr    % & ' ) + , - . / L M N P R S T U V { ͹uu/hh5B*CJOJQJ\^JaJph h5CJOJQJ\^JaJ&hh5CJOJQJ\^JaJ hAh&hAh5CJOJQJ\^JaJ hilh h5\&hkh5CJOJQJ\^JaJ h5CJOJQJ\^JaJ.+3@rx~ $Ifgd5YFf $$Ifa$gd5Y  ^ `gdil$a$gdU$a$gdn(gdn(<33' $$Ifa$gd5Y $Ifgd5Ykd$$Ifl4ֈJ t"")/5 T  o 9 044 laf40kd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y   $$Ifa$gd5Y $Ifgd5Y  & ( <33' $$Ifa$gd5Y $Ifgd5Ykd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4( ) , . / 0kd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y/ = M O P S U $$Ifa$gd5Y $Ifgd5YU V n { } <33' $$Ifa$gd5Y $Ifgd5Ykd $$Ifl4ֈJ t"")/5 T  o 9 044 laf4{ | ~       @ A C E F G H I a b d f g h i j k p q Լۧ/hh5B*CJOJQJ\^JaJph)h5B*CJOJQJ\^JaJph/hh5B*CJOJQJ\^JaJph hAh&hh5CJOJQJ\^JaJ h5CJOJQJ\^JaJ8} ~ 0kdH $$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y $$Ifa$gd5Y $Ifgd5Y :11% $$Ifa$gd5Y $Ifgd5Ykdb $$Ifl4ֈJ t"")/5 T  o 9 044 laf4 0kd $$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y $$Ifa$gd5Y $Ifgd5Y   <33' $$Ifa$gd5Y $Ifgd5Ykd $$Ifl4ֈJ t"")/5 T  o 9 044 laf4     0kd $$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y ) @ B C F H $ !$Ifa$gd5Y $$Ifa$gd5Y $Ifgd5YH I T a c <33' $$Ifa$gd5Y $Ifgd5Ykd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4c d g i j 0kd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Yj k l m n o p $$Ifa$gd5Y $Ifgd5Yp q } <33' $$Ifa$gd5Y $Ifgd5Ykd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 0kd*$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y       = > @ A B C D E s t v x y z { |    ۼۼ/hh5B*CJOJQJ\^JaJph hAh&hh5CJOJQJ\^JaJ h5CJOJQJ\^JaJH $$Ifa$gd5Y $Ifgd5Y <33' $$Ifa$gd5Y $Ifgd5YkdD$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 'kd^$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y $Ifgd5Y $$Ifa$gd5Y $Ifgd5Y   <33' $$Ifa$gd5Y $Ifgd5Ykdx$$Ifl4ֈJ t"")/5 T  o 9 044 laf4     0kd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y + = ? @ B D $$Ifa$gd5Y $Ifgd5YD E S s u <33' $$Ifa$gd5Y $Ifgd5Ykd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4u v y { | 0kd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y| $$Ifa$gd5Y $Ifgd5Y <33' $$Ifa$gd5Y $Ifgd5Ykd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 0kd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y $$Ifa$gd5Y $Ifgd5Y  :11% $$Ifa$gd5Y $Ifgd5Ykd$$Ifl4ֈJ t"")/5 T  o 9 044 laf4     .kd2$$Ifl4ֈJ t"")/5 T  o 9 044 laf4 $$Ifa$gd5Y    7 = > L M N ` n g i n 7=Ʈ~m~mU/h@h5B*CJOJQJ\^JaJph h5CJOJQJ\^JaJ&hFAh5CJOJQJ\^JaJ hkh)h5B*CJOJQJ\^JaJph/hkh5B*CJOJQJ\^JaJph)hkhB*CJOJQJ^JaJph hkhCJOJQJ^JaJ&hkh5CJOJQJ\^JaJ    + , 7 > M $$Ifa$gdAxH $$Ifa$ $ !$Ifa$$If $$Ifa$gdilM N ` p } ~ OI<3I $IfgdP  $IfgdP$IfkdP$$Ifl4r %-j5K044 la~  i j 89KL $IfgdY $Ifgd#cc $Ifgd^U  !$Ifgd^U  !$If$If $Ifgd^U !"#7G::: $Ifgdnkd$$Iflr %-j5K044 la $Ifgd^U !#%.8:Y"%abίίίΘ΃kSS85hP1h56B*CJOJQJ\]^JaJph/h@h5B*CJOJQJ\^JaJph/h56B*CJOJQJ\]^JaJph)h=C5B*CJOJQJ\^JaJph,h5B*CJH*OJQJ\^JaJph/hkh5B*CJOJQJ\^JaJph hkh)h5B*CJOJQJ\^JaJph7hnh5B*CJOJQJ\^JaJmH phsH 789:YZ[qr&'"#de [\ !$H$IfgdkL !$7$8$H$Ifgd#cc $IfgdZ' $If^gdZ'gh45#$AB!" q!r! !$7$8$H$Ifgd&P !$H$Ifgd&P !$7$8$H$Ifgd#ccDFno~ !'w = W ` ѷѠяpp\pHpHpHpH&hX4h5CJOJQJ\^JaJ&hfh5CJOJQJ\^JaJ h5CJOJQJ\^JaJhCJOJQJ^JaJ hkLhCJOJQJ^JaJ,h5B*CJH*OJQJ\^JaJph2hh5B*CJH*OJQJ\^JaJph)h5B*CJOJQJ\^JaJph2h=;<h5B*CJH*OJQJ\^JaJph !! !-!!!#"###$#%#&#h#{#$%%&&&'''K'm''''))))****N+++++++ƮƮƧۓۓۓۓۓۓۮƮƮƮƮƮhh5CJ\aJ&hh5CJOJQJ\^JaJ hkh/hkh5B*CJOJQJ\^JaJph)h5B*CJOJQJ\^JaJph h5CJOJQJ\^JaJ&h4h5CJOJQJ\^JaJ/r!!!|"}"~""#$#%# !$7$8$H$IfgdZ' !$H$Ifgd !-$7$8$H$If^-gd#cc !$7$8$H$If^gdQ !$7$8$H$Ifgd&P%#&#>#?#@#A#B#PG:::: $If^gd $Ifgd kd$$Iflr %-j5K044 laB#C#S#^#g#h#$$%%''m'n'''(( !dh$H$Ifgd !dh$H$Ifgd !dh$7$8$H$Ifgd6Z !dh$7$8$H$Ifgdq2 $Ifgd $If^gd (())))))))))))**5*6*7*8*9*:*;*<*=*>* !$H$Ifgd@ !dh$H$Ifgd5>*U*f*g*h*i*j*k*l*m*n*o*p*q*r*s*t*u*}*~********* !$H$Ifgd@**********************#+$+%+&+'+ !$H$IfgdL !$H$Ifgd@'+(+)+*+++,+-+.+/+0+1+2+M+N+++ !$H$Ifgd@ !$H$IfgdL+++++++PGGGG9  !$Ifgd $Ifgd kd $$Iflr %-j5K044 la+++++++,,),[,g,, - ----:-p-q-s-t-u-v---ζζζ㶗}rnVrn/h@h5B*CJOJQJ\^JaJphhhd^h5>*\2h,h5<B*CJOJQJ\^JaJph/h,h5B*CJOJQJ\^JaJph hkh/hkh5B*CJOJQJ\^JaJph)h5B*CJOJQJ\^JaJph7hkh5B*CJOJQJ\^JaJmH phsH +++++,,BkdC!$$Iflr %-j5K044 la  !$Ifgd ,,),7,[, - - - - - $Ifgd@, $Ifgdv} $Ifgdi $Ifgd ----:-;-q-PGG>>> $Ifgdi $Ifgd kd!$$Ifl3r %-j5K044 laq-r-s-t-u-v--G>>5 $Ifgdi $Ifgd kd"$$Ifl3r %-j5K044 la $Ifgd@,----....>kdw#$$Ifl3r %-j5K044 la $Ifgd@, $Ifgdi-......<.=..........////ζ|qg`K)hd^hB*CJOJQJ^JaJph hd^hh8h5\ *h8h5\hhxh>*hd^h5>*\7hkh5B*CJOJQJ\^JaJmH phsH  hkh/hkh5B*CJOJQJ\^JaJph/h8h5B*CJOJQJ\^JaJph2 *h8h5B*CJOJQJ\^JaJph...<.=...... $Ifgd@, $Ifgdi $Ifgd ....../PGG>>> $Ifgdi $Ifgd kd3$$$Ifl3r %-j5K044 la///// /n/G>>5 $Ifgdi $Ifgd kd$$$Ifl3r %-j5K044 la $Ifgd@,// /n/o//90:0<0=0>0?0a0c000000000111111M1O1t1ĿϖĎyϖĎ_ϖĎPh8hB*CJaJph2hd^h5>*B*CJOJQJ\^JaJph)hd^hB*CJOJQJ^JaJphh5>*\ hkh,hd^h>*B*CJOJQJ^JaJphh hd^h h>*hd^h5>*\/hkh5B*CJOJQJ\^JaJph/h@h5B*CJOJQJ\^JaJphn/o///:0;0<0=0>kd%$$Ifl3r %-j5K044 la $Ifgd@, $Ifgdi=0>0?0b0c0000 $Ifgd@, $Ifgdi $Ifgd 0000000PGG>>5 $Ifgdd^ $Ifgdi $Ifgd kdm&$$Ifl3r %-j5K044 la0111111>55 $Ifgd kd)'$$Ifl3r %-j5K044 la $Ifgd@, $Ifgdd^1N1O1u111111 $Ifgd@, $Ifgdit111111 2"2#2$2%2&2C2f222J3N3O3P3Q3x3y3z33333~444444̰̰̰̰̰̎Ű}̰̰ḛ/hp*nh5B*CJOJQJ\^JaJph!h\hB*OJQJ^Jph/hh5B*CJOJQJ\^JaJphhOJQJ^J)h5B*CJOJQJ\^JaJph hkh/hkh5B*CJOJQJ\^JaJphh8hB*CJaJphhB*CJaJph!1111112PJJ<<<  !$IfgdX-R$Ifkd'$$Ifl3r %-j5K044 la2 2!2"2#2$2C2B<$Ifkd($$Iflr %-j5K044 la  !$IfgdX-RC2g2222 3 3 3K3L3M3N3O3  !$Ifgd9  !$IfgdX-R$If O3P3Q3w3x3PBB0 !8$If^8gdD  !$IfgdDkd])$$Iflr %-j5K044 lax3z333333~44z$7$8$H$If^gdp*nR & F$7$8$Eƀ zF.H$Ifgdp*n $7$8$H$Ifgds $IfgdD $Ifgd\444444 $7$8$H$Ifgdv} $7$8$H$IfgdsR & F$7$8$Eƀ zF.H$IfgdU~7444 55,515@5PJJJDJJ$If$Ifkd*$$Iflr %-j5K044 la4 55,55555555555556 6!6E6D7E788)9*9991:2:u:v::˶˲~˅~˅˅˅˅˅g˅˅~,h5B*CJH*OJQJ\^JaJph hkh)h5B*CJOJQJ\^JaJph/h#h5B*CJOJQJ\^JaJphh)hkhB*CJOJQJ^JaJph/hkh5B*CJOJQJ\^JaJph7hkh5B*CJOJQJ\^JaJmH phsH  @5G55555555555555 !$7$8$H$IfgdY !dh$7$8$H$Ifgd# !dh$7$8$H$Ifgdk$If55555PEE6 !$If^  !$Ifkd*$$Iflr %-j5K044 la555 6!6E7F7(8)88899999999999::  !$If $Ifgd  !$Ifgd^)#$If $If^:2:3:4:5:6:7:8:9:::;:u:  !$If u:v::::::PBBBB9 $IfgdZ'  !$IfgdZ'kd+$$Iflr %-j5K044 la:::;;;;<<:<<<<!==>$If[$\$gdH6s$If[$\$gdv$If[$\$gdH6s$If[$\$gdv $Ifgdv /$Ifgd8 $Ifgd8 /$Ifgd1Q+  !$IfgdZ' $IfgdZ':;;;;;;<<<<9<>>.?* hh# *hmd hCJOJQJ^JaJhCJOJQJ^JaJ hmd hCJOJQJ^JaJ)h5B*CJOJQJ\^JaJph/hkh5B*CJOJQJ\^JaJph2hkh5<B*CJOJQJ\^JaJph>>??j@k@5A6ARASAyAzAAAAA C C,C)E*E  !$IfgdH6s  $7$8$H$IfgdH6s $Ifgd8 /$Ifgd8$If[$\$gdH6s $IfgdH6sRAxAzAAAAAB8BBBC C C C C,CACuCC'E(E)EFF#F$FAFFF(K)K³¥uundYQjh} Uh +&hB*phh8h5\ h hh hB*ph h5\hB*phh8hB*phh h8hhCJOJQJ^JaJ *hCJOJQJ^JaJ# *hhCJOJQJ^JaJ(h@hCJOJQJ^JaJmH sH + *h@hCJOJQJ^JaJmH sH *EFF$FFF2I3IKKKKKKKLLLM $Ifgd8 /$Ifgd8 d$*$Ifgdv d$*$IfgdH6s  $7$8$H$IfgdH6s $IfgdH6s  !$IfgdH6s)KOKPKcKdKKKKKKKLLDMEM{M|MMMNpS W"W>W?WbWcWdWҝ|dO)hhB*CJOJQJ^JaJph/hmd h5B*CJOJQJ\^JaJph hhCJOJQJ^JaJ hd{hh'n^h0J$# *hhCJOJQJ^JaJ# *hmd hCJOJQJ^JaJ hmd hCJOJQJ^JaJhCJOJQJ^JaJ hvhhhh0J$jh} Uh} MMNNO)O[OOO]PPQRpSSSTTUU W$ d@$If` a$gdH6s$d@$If`a$gdH6s$d@$If`a$gdH6s  $7$8$H$IfgdH6s W!W"W>W?WcWdWWWWWWWWW&X'XRXSXYYZ $IfgdH6s d$*$IfgdH6s $Ifgdmd /$IfgdH6s /$Ifgd1Q+ $Ifgd8 /$Ifgd8dWWWWWWWW%X'XQXSXuXYYZZZëngcXP8/hkh5B*CJOJQJ\^JaJphhB*phhm/&hCJaJh h8h, *hmd hB*CJOJQJ^JaJph)hhB*CJOJQJ^JaJph hmd hCJOJQJ^JaJ/hmd h5B*CJOJQJ\^JaJph#hB*CJOJQJ^JaJph& *hB*CJOJQJ^JaJph, *hhB*CJOJQJ^JaJphZZZZ [ [ [!["[#[$[%[&['[([)[*[+[,[-[.[/[0[1[2[3[4[ $Ifgd8l $Ifgd /$Ifgd1Q+4[5[6[7[8[9[:[;[S[T[h[i[j[k[l[m[n[o[p[q[r[s[t[u[v[w[x[y[z[ $Ifgd z[{[|[}[~[[[[[[[[[[[[[[[[[[[[[[[[[ $Ifgd [[[[[[[[[[[[[[[[[[[[[[[[[[[[ $Ifgd8l $Ifgd [[[[[[[[[[[[[[[[[[[[[[[[[[[[[ $Ifgd8l[[[\\\\\\\\\ \ \ \ \ \\\\\\\\\\\5\6\ $Ifgd8l6\J\K\L\M\N\O\P\o\p\\\\\\\\\\\\\\\\\\\ $Ifgd8l $Ifgd Z\\S^T^U^^__{`|```aaaaaNbObbbbbbbbbjjkkkkllQmUmVmmmmmmmmm꺳Ҙҳ)h=C5B*CJOJQJ\^JaJph5hkhh68$5B*CJOJQJ\^JaJph hkh/hh5B*CJOJQJ\^JaJph/hkh5B*CJOJQJ\^JaJph)h5B*CJOJQJ\^JaJph.\\\\\\\\\\\\\\\\\\]]]]]]]]] ]!] $Ifgd !]"]#]$]%]&]'](])]*]+],]-].]/]0]1]2]3]4]5]6]7]8]9]:];]<]=] $Ifgd =]>]?]@]A]B]C]D]E]F]G]H]I]J]K]L]M]]]]]]]]]]]]] $Ifgd ]]]]]]]]]]]]]]]]]]]]]]]]]]]]] $Ifgd ]]]]]]]]]]]]]]]]]]]]]]]]]]]]] $Ifgd ]]]]]]]^^^^^^^^T^ $Ifgd T^U^n^o^p^q^r^PEEEEE  !$IfkdM,$$Iflr %-j5K044 lar^^^^^^^(_)_*_+_,_-_._/_0_1_M_N_k_l_____ $7$8$H$IfgdC  !$If !$Ifgd~_______```Y`Z`[`s`t`u`v`w`x`y`z`{`|`}`~``` $7$8$H$Ifgd $7$8$H$Ifgdv}```````` $7$8$H$Ifgd`` aa3a:aaPEEEE7  !$Ifgdc  !$Ifkd -$$Iflr %-j5K044 laaaaaaaaBkd-$$Ifl r %-j5K044 la  !$IfgdcaaaaaLbMbNbObhbibbbb $Ifgdp  !$Ifgd1 bbbbbccPBBB99 $Ifgd !  !$Ifgd !kd.$$Iflor %-j5K044 lacneoe4g5gkghhh iSiiijQjkkkkkl $Ifgd !lll&l6lPmQmPBBB99 $Ifgd !  !$Ifgd !kd=/$$Ifl r %-j5K044 laQmRmSmTmUmVmWmnmompmmmmmm $Ifgdh. $Ifgd !mmmmmmmmPJJJECCgd !7$8$H$kd/$$Ifl r %-j5K044 lammmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmҾ}skhCJaJh0J!CJaJh=C0J!mHnHuh h0J!jh} 0J!Uhl~Oh5CJ\aJ h5\h,ljh,lU&hkh5CJOJQJ\^JaJ/hkh5B*CJOJQJ\^JaJph)hkhB*CJOJQJ^JaJph mmmmmmmmmmmmmmmmmmgd !&`#$$a$< 0&P1h0:p@= /!"#$ % $$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l4 <05 55T55o59/ /  /  /  f4p<kd$$Ifl4ֈJ t"")/5     T      o   9    <044 laf4p<$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4&$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/  / / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4*$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/  / / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh5 55T55o59#v #v#vT#v#vo#v9:V l405 55T55o59/ / / /  f4$$If!vh555K55#v#v#vK#v:V l40555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l30,555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l30555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l0555K5$$If!vh555K55#v#v#vK#v:V l 0555K5$$If!vh555K55#v#v#vK#v:V lo0555K5$$If!vh555K55#v#v#vK#v:V l 0555K5$$If!vh555K55#v#v#vK#v:V l 0555K5^ 888888888666666666vvvvvvvvv62622686662662666666666666666666668662266666666666622666228H66666266666666666666666666666666666666666666666666666666666666662062 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH 8`8 rNormal_HmH sH tH TT [l0 Heading 1$ & @&a$5CJOJQJ\^JaJ:@: [l0 Heading 2$@&5\LL [l0 Heading 3$@&>*CJOJQJ^JaJB@B [l0 Heading 4$@&5CJ\aJ>> [l0 Heading 5 $@&a$5\>> [l0 Heading 6 $ F@&5\:: [l0 Heading 7$@&6]B@B [l0 Heading 8$@&5CJ\aJD D [l0 Heading 9 $@&>*OJQJ^JDA`D Default Paragraph FontRi@R 0 Table Normal4 l4a (k ( 0No List RR P0Heading 1 Char5CJ KH OJQJ\^JaJ TT P0Heading 2 Char 56CJOJQJ\]^JaJNN P0Heading 3 Char5CJOJQJ\^JaJN!N P0Heading 4 Char5CJOJQJ\^JaJT1T P0Heading 5 Char 56CJOJQJ\]^JaJFAF P0Heading 6 Char5OJQJ\^JHQH P0Heading 7 CharCJOJQJ^JaJNaN P0Heading 8 Char6CJOJQJ]^JaJ@q@  P0Heading 9 Char OJQJ^JH"@H [l0Captiona$5CJOJQJ\^JaJBBB [l0 Body TextCJOJQJ^JaJ@@ P0Body Text Char CJ^JaJ@P@ [l0 Body Text 25CJ\aJDD P0Body Text 2 Char CJ^JaJ4@4 [l0Header !:: P0 Header Char CJ^JaJ4 @4 [l0Footer !:: P0 Footer Char CJ^JaJ2)@2 [l0 Page Number^J>Q"> #[l0 Body Text 3"a$CJaJD1D "P0Body Text 3 Char CJ^JaJ:U@A: [l0 Hyperlink>*B*^JphHRH &[l0 Balloon Text%CJOJQJ^JaJFaF %P0Balloon Text Char CJ^JaJJ^rJ [l0 Normal (Web)'dd[$\$CJaJ2>@2 )[l0Title(a$CJ$aJ$JJ (P0 Title Char5CJ KHOJQJ\^JaJ JVJ [l0FollowedHyperlink>*B* ^Jphb/b zu10Default +7$8$H$-B*CJOJQJ^J_HaJmH phsH tH 66 -zu10 Footnote Text,HH ,P0Footnote Text Char CJ^JaJD&D zu10Footnote ReferenceH*^Jfof @,0 GroupWiseView/1$7$8$H$$CJOJQJ^J_HaJmH sH tH rr q0 Table Grid7:V000CJaJXX oG0font51dd[$\$#5B*CJOJQJ\^JaJphN"N oG0font62dd[$\$5CJOJQJ\^JaJ>2> oG0xl663dd[$\$a$CJaJ>B> oG0xl674dd[$\$a$CJaJ|R| oG0xl68?5ddNOPQ[$\$a$5CJOJQJ\^JaJxbx oG0xl69<6ddNOPQ[$\$5CJOJQJ\^JaJLrL oG0xl707dd[$\$5CJOJQJ\^JaJhh oG0xl71+8ddM N[$\$a$5CJOJQJ\^JaJ oG0xl72A9ddM OPQ[$\$a$#5B*CJOJQJ\^JaJph oG0xl73A:ddM OPQ[$\$a$#5B*CJOJQJ\^JaJph|| oG0xl746;ddM OP[$\$a$#5B*CJOJQJ\^JaJph oG0xl75A<ddM OPQ[$\$a$#5B*CJOJQJ\^JaJph oG0xl76A=ddM OPQ[$\$a$#5B*CJOJQJ\^JaJphpp oG0xl773>ddM NO[$\$5CJOJQJ\^JaJ~~ oG0xl78B?dd9DM NOP[$\$5CJOJQJ\^JaJ~~ oG0xl79B@dd9DM NOP[$\$5CJOJQJ\^JaJ~~ oG0xl80BAdd9DM NOP[$\$5CJOJQJ\^JaJ|"| oG0xl81@Bdd9DNOPQ[$\$5CJOJQJ\^JaJ|2| oG0xl82@Cdd9DNOPQ[$\$5CJOJQJ\^JaJbBb oG0xl83&DddPQ[$\$5CJOJQJ\^JaJhRh oG0xl84+EddM N[$\$a$5CJOJQJ\^JaJpbp oG0xl853FddM NQ[$\$5CJOJQJ\^JaJ|r| oG0xl86@Gdd9DNOPQ[$\$5CJOJQJ\^JaJ oG0xl87LHdd9DNO PQWDd[$\$`d`d5CJOJQJ\^JaJ|| oG0xl88@Idd9DNOPQ[$\$5CJOJQJ\^JaJ~~ oG0xl89AJdd9DOPQWD[$\$``5CJOJQJ\^JaJ oG0xl90LKdd9DNOPQWD[$\$``5CJOJQJ\^JaJ|| oG0xl91@Ldd9DNOPQ[$\$5CJOJQJ\^JaJ|| oG0xl92@Mdd9DNOPQ[$\$5CJOJQJ\^JaJ oG0xl93LNdd9DNO PQWDd[$\$`d`d5CJOJQJ\^JaJ|| oG0xl94@Odd9DNOPQ[$\$5CJOJQJ\^JaJ|| oG0xl95@Pdd9DNOPQ[$\$5CJOJQJ\^JaJ oG0xl96LQdd9DNOPQWD[$\$``5CJOJQJ\^JaJ|"| oG0xl97@Rdd9DNOPQ[$\$5CJOJQJ\^JaJ2 oG0xl98LSdd9DNO PQWDd[$\$`d`d5CJOJQJ\^JaJB oG0xl99YTdd9DM NO PQWDd[$\$`d`d5CJOJQJ\^JaJR oG0xl100AUdd9DO PQWDd[$\$`d`d5CJOJQJ\^JaJzbz oG0xl101<VddNOPQ[$\$5CJOJQJ\^JaJzrz oG0xl102<WddNOPQ[$\$5CJOJQJ\^JaJzz oG0xl103<XddNOPQ[$\$5CJOJQJ\^JaJ^^ oG0xl104 YddM [$\$a$5CJOJQJ\^JaJ oG0xl105CZdd9DM O QWDd[$\$`d`d5CJOJQJ\^JaJ oG0xl106I[ddM NOPQ[$\$5CJOJQJ\^JaJ~~ oG0xl107@\dd9DNOPQ[$\$5CJOJQJ\^JaJ~~ oG0xl108?]ddNOPQ[$\$a$5CJOJQJ\^JaJhh oG0xl109<^ddNOPQ[$\$CJaJff oG0xl110(_ddM O[$\$5CJOJQJ\^JaJvv oG0xl1117`dd9DM OP[$\$5CJOJQJ\^JaJ oG0xl112Madd9DM NOPQ[$\$5CJOJQJ\^JaJ" oG0xl113IbddM NOPQ[$\$5CJOJQJ\^JaJ2 oG0xl114IcddM NOPQ[$\$5CJOJQJ\^JaJB oG0xl115Addd9DNO QWDd[$\$`d`d5CJOJQJ\^JaJR oG0xl116Cedd9DNOPQ[$\$a$5CJOJQJ\^JaJvbv oG0xl1178fdd9DNOQ[$\$a$5CJOJQJ\^JaJr oG0xl118Pgdd9DM NOPQ[$\$a$5CJOJQJ\^JaJvv oG0xl1198hdd9DOPQ[$\$a$5CJOJQJ\^JaJ oG0xl120Cidd9DNOPQ[$\$a$#5B*CJOJQJ\^JaJph oG0xl121Ejdd9DM NPQ[$\$a$5CJOJQJ\^JaJ oG0xl1228kdd9DNOQ[$\$a$#5B*CJOJQJ\^JaJphll oG0xl123-ldd9DOQ[$\$a$5CJOJQJ\^JaJpp oG0xl124Cmdd9DNOPQ[$\$a$CJaJtt oG0xl125+nddM P[$\$a$#5B*CJOJQJ\^JaJph oG0xl126AoddM OPQ[$\$a$#5B*CJOJQJ\^JaJph oG0xl127Mpdd9DM NOPQ[$\$5CJOJQJ\^JaJ oG0xl128Pqdd9DM NOPQ[$\$a$5CJOJQJ\^JaJ" oG0xl129Crdd9DNOPQ[$\$a$5CJOJQJ\^JaJV2V oG0xl130sdd9D[$\$a$5CJOJQJ\^JaJlBl oG0xl131-tdd9DNO[$\$a$5CJOJQJ\^JaJvRv oG0xl1328udd9DNOQ[$\$a$5CJOJQJ\^JaJxbx oG0xl133:vdd9DM NP[$\$a$5CJOJQJ\^JaJr oG0xl134Ewdd9DM NOP[$\$a$5CJOJQJ\^JaJ oG0xl135Pxdd9DM NOPQ[$\$a$5CJOJQJ\^JaJ oG0xl136Pydd9DM NOPQ[$\$a$5CJOJQJ\^JaJvv oG0xl1378zdd9DOPQ[$\$a$5CJOJQJ\^JaJ oG0xl138P{dd9DM NOPQ[$\$a$5CJOJQJ\^JaJ oG0xl139E|dd9DM NOP[$\$a$5CJOJQJ\^JaJ oG0xl140P}dd9DM NOPQ[$\$a$5CJOJQJ\^JaJxx oG0xl141:~dd9DM NP[$\$a$5CJOJQJ\^JaJ oG0xl142Pdd9DM NOPQ[$\$a$5CJOJQJ\^JaJ oG0xl143Pdd9DM NOPQ[$\$a$5CJOJQJ\^JaJ oG0xl144Pdd9DM NOPQ[$\$a$5CJOJQJ\^JaJ" oG0xl145Pdd9DM NOPQ[$\$a$5CJOJQJ\^JaJ2 oG0xl146Pdd9DM NOPQ[$\$a$5CJOJQJ\^JaJvBv oG0xl1478dd9DOPQ[$\$a$5CJOJQJ\^JaJlRl oG0xl148-dd9DOP[$\$a$5CJOJQJ\^JaJlbl oG0xl149-dd9DOQ[$\$a$5CJOJQJ\^JaJlrl oG0xl150-dd9DOQ[$\$a$5CJOJQJ\^JaJvv oG0xl1518dd9DOPQ[$\$a$5CJOJQJ\^JaJvv oG0xl1528dd9DNOP[$\$a$5CJOJQJ\^JaJvv oG0xl153Cdd9DNOPQ[$\$a$5CJ\aJjj oG0xl1548dd9DNOP[$\$a$5CJ\aJpp oG0xl155Cdd9DNOPQ[$\$a$CJaJdd oG0xl1568dd9DNOP[$\$a$CJaJ oG0xl157Cdd9DNOPQ[$\$a$5CJOJQJ\^JaJ oG0xl158AddM OPQ[$\$a$#5B*CJOJQJ\^JaJph\ \ oG0xl159ddQ[$\$a$5CJOJQJ\^JaJh h oG0xl160)ddPQ[$\$a$5CJOJQJ\^JaJv" v oG0xl1618dd9DNPQ[$\$a$5CJOJQJ\^JaJt2 t oG0xl1626ddM NO[$\$a$5CJOJQJ\^JaJtB t oG0xl1636ddM NQ[$\$a$5CJOJQJ\^JaJDR D xW#0opcdd[$\$a$5B* \ph6b 6 90hddd[$\$CJaJ8r 8 90regdd[$\$CJaJ.W . 1~0Strong 5\^J( ( 0msoins^J.O . H6s0p2dd[$\$.O . H6s0p3dd[$\$.O . H6s0p1dd[$\$PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] eh !6669{   +-/t14:RA)KdWZmm7@N^dghqw{ ( / U }   H c j p   D u |   M ~ 7r!%#B#(>**'+++, -q--../n/=000112C2O3x344@555:u::>*EM WZ4[z[[[[6\\!]=]]]]T^r^_``aabclQmmmm89:;<=>?ABCDEFGHIJKLMOPQRSTUVWXYZ[\]_`abcefijklmnoprstuvxyz|}~(COCcCDE{EEeXX!(*9!!8@0(  B S  ?/!R# "R4$ #R# $R! %R4! &R" 'R4" (Rt" )R*R+R,,Rl-R.R/Rl0R,1R,2Rl3R4Rl\5R^6Rl^7Rl_8R,_9R,^:R[;R,\Rt5?R5@R5ARt5BR5CR45DR45ER5FR5GRܚHR\IR\JRKR\LRMRNRܘOR3r c c I I E BBPYYCCHYer&e      !"#$%&'()*+,-. ? k k Q Q P/L__``GNNfm)e  !"#$%&'()*+,-. B*urn:schemas-microsoft-com:office:smarttagscountry-region:*urn:schemas-microsoft-com:office:smarttagsStreet=%*urn:schemas-microsoft-com:office:smarttags PlaceName='*urn:schemas-microsoft-com:office:smarttags PlaceType8)*urn:schemas-microsoft-com:office:smarttagstime?**urn:schemas-microsoft-com:office:smarttags stockticker8-*urn:schemas-microsoft-com:office:smarttagsdate8,*urn:schemas-microsoft-com:office:smarttagsCity9.*urn:schemas-microsoft-com:office:smarttagsplace9/*urn:schemas-microsoft-com:office:smarttagsState XY 010121819200920102122304569DayHourMinuteMonthYear/.- ,.*) - '.%- /./.'.%%.%*-  -  .- '.%)  ,..%.'.-*/8Viqx}")*0 -6xOU"-CJKQz  ""!"4"N"T"""k#p###$$%% &&&&&&((j)t)u)|)z+++++2123333B9G9I9Q9S9[9999999N@W@CCCCCCCDD D*G+GGGIIUIJJ?OGOlOnOOOP!P/P1PHPMPSSLSRSSSCTITwVViXrXYYY0YYY]ZgZ\\bcocvcccgeme}eeeeeeeeeeeeeeee&Ary!!""$$$($,,, -k/y/0169Q9S9x9\\]]aaQbZbeeeeeeeeeeeeee333333333333 rXrXbbeeeeeeeeeeeeeeeeee zzJ.q/ (0-b?Lf12>x][D!v2JX&N `57&<jLlJ <pt;N c>QERn-BUA"Zln ȳFrztw^`^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^J. ^`OJQJo(pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`OJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^Jo(.ee^e`^J.5L5^5`L^J.  ^ `^J.  ^ `^J.L^`L^J.uu^u`^J.EE^E`^J.L^`L^J.0^`0^Jo(. ^`OJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(^`^Jo(.e^e`^J.5L^5`L^J. ^ `^J. ^ `^J.L^`L^J.u^u`^J.E^E`^J.L^`L^J.^`^Jo(.dd^d`^J.4L4^4`L^J.  ^ `^J.  ^ `^J.L^`L^J.tt^t`^J.DD^D`^J.L^`L^J.^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. ^`OJQJo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(^`^J.TT^T`^J.$ L$ ^$ `L^J.  ^ `^J.^`^J.L^`L^J.dd^d`^J.44^4`^J.L^`L^J.^`^J.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. `5b?Fr][D! zpt;NERztc>Q&<1lnBU/ 2JX&lJ                                                               Z)s        D"                                                              x)+x)x)x)x)x)x)<<<x)x) x)!x)"x)#x)$x)<<<%x))x)&x)x)'x)*x)(x))x)<<<*x)<<<+x)000 ,x)-x).x)/x)0x)*x)1x)2x)*x)3x)S{LS.Lk%E"G~m(2Z=_h'7\3G Xx 6 ? C sE } r0 C G T md #y 2| A ! d J  0. 1AG'y[ ,=@|Jx34AHe!p-/FW\Tik)JqWusV~ *\Qo1B d6F{\LQ)UeyySe1zAn.|/<tY*43l>U^ExQK @W\&bBcj) -c l  ! ! 8!A!"""^)#xW#c#&$68$D$\_$if$ %%&%C%E%eR% +&m/&b&e& ( (F(O(e(p(X)_)3*6+$ ++1Q+2Q+g[+@,d, -%-G.f.9 /4/F/V^/n/r/30=0F0I01p 1%+1P1zu1A2D3V3Y3|^3G%4K.4X4&5T5"5G5nK5u6.%6]67H7W]7lh7/i7U~778w9}9@93:A:{:|:?$;</<=;<VG<hc= > ?W ?3?N@0AsA(A=AFA#B]]BI`BCw9C=Cr>CIC)OC"`CgC4D^8Dd\D_jDE EK Eb?EfE/FUFaFpFQIGoGCHaHAxH\IoI`wIV~I# J JJJ ;KeaKrKkL1,M5M{M^Ol~O-#Pt#P&P63PZPkP)QaQhQ"oQaRT)RX-R\ZRNS%T.'TMThT)U_?U@U^U=VbVtVWlvW$XpX4X5XAXYY6Y5Y\9Z[U[b[5 \\*\Z/\M0\`O\T\i]E*]/];]O]:P]j]p]V^'n^>__4$_@_^`/e`ba"a3b9FbZb\bbb0c5cQOcbc#ccZ~cfdrdydeRelere~ehdhthiBi{j0k(k7kgk l8l,l8lil8m @mnnp*nG,n/n;nBnHn~Wnen@NofSop7KpUlpqVqqq!qgVqlqrq^rsssH6sltwts u:)u+u]unuc v;1vDvIvG wwi)wQ)x1xXx2yOyRFz;{d{ |L |?|Nb|i|>}C}v}~%~G~S~A1 @NTw(Pn~"[ >n1~M mOh.MkH2?LUqkqphw +L`m"49DFYHYM%;?6ZP.8Pof'u#+hUW}d^ 1&uFFRgOrwy'*7dH>` ,pxwL++IpiS ~8fUWry#7!o-D2|W^FSW^Xt} % 0= _U2iXdvo 8PTbV  /,;_oLtb >gIYgguJ% do8qBHHeg>os'/5GK~q)'4L>VVpXvZ'vCugZ?Pq#.h w^#fHnO T|O5Yr#(Fz{ &T2eo{j+SUj,p8@ILi-Gq2\='x &.` W' $,|/Xd}BuQU*lOz 9k&}6VCikm 1+m[4SMguYC~<OUS-:t.n%];Qz\(LQ,#4:CWzciqiH~ J0] xI,8\3Yime{}R,5cOioG}@Y$uh3_!6tF(\UkKy'Tt|y8UUjw (C1jlS8 HWnBkHeRUo* ,ti TjN[lOL*TUB`F`^x'@,PXl[/1Va>x"ify|~+'w s# vRvJNJ`l u'Q,c2Zli$9=H)RP??Jq>7rDoGRDLj96(;AUc$D}RxS2Alr~&G`dyY")p*56>PF;QFrV d*;QFb6@<kH( >ee@ex@Unknown G*Ax Times New Roman5Symbol3. *Cx Arial5. .[`)Tahoma7K@Cambria7.@ CalibriqBJDDEA+TimesNewRomanTimes New Roman?= *Cx Courier New;WingdingsA BCambria Math"1hb&b&s.V3.V3!0ee2H ?d,p2! xxMaryland Board of PharmacyJanet BarnicleLaToya SimmonsL           Oh+'0h   $ 0 <HPX`Maryland Board of PharmacyJanet BarnicleNormalLaToya Simmons2Microsoft Office Word@Ik@;@]!@]!.Vharmacyboard2lhttp://www.dsd.state.md.us/+$Comments of draft 797 regs for MD Cynthia.Anderson@omnicare.comAndersonmentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100011000Microsoft.Office ?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      "#$%&'(H+,-./0;58O9:<=>?@ABCIPQRSTU)Root Entry F`s(?f7Data 01TableWordDocument>hSummaryInformation(!DocumentSummaryInformation8,CompObjyMsoDataStore`s(?f`s(?f -./0123456789:;<=>?@ABCJKLMNOPQR  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q as.microsoft.com/office/2006/metadata/longProperties"/>US3USYD5BJ==2 `s(?f`s(?fItem  PropertiesK3W3EC3UVBW==2 `s(?f`s(?fItem  Properties H5B1WU0U4C==2`s(?f`s(?fItem *PropertiesyBB] es"/> This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision. e name="AssociationName" type="xs:string"> cumentation> This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision. Microsoft.Office.Docume, Cynthia%7316cdcd-2f92-4743-8604-9d5ad483aba28000.00000000000JHQQSZKKEHZ5-11-80ihttp://dev.dhmh.maryland.gov/pharmacy/_layouts/DocIdRedir.aspx?ID=JHQQSZKKEHZ5-11-80, JHQQSZKKEHZ5-11-80)0x010100EED954EFFD171EntManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100021001Microsoft.Office.DocumentManagement, Version=14.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100041002Microsoft.Office.DocumentManagement, Version=14.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100061003Microsoft.Office.DocumentManagement, Version=14.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandler> ent> DocumentLibraryFormDocumentLibraryFormDocumentLibraryForm429cMicrosoft.Offic w>Microsoft. lter>Document ID GeneratorSynchronous100011000Microsoft.Office.DocumentManagement, Version=14.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100021001Microsoft.Office.DocumentManagement, Version=14.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100041002Microsoft.Office.DocumentManagement, Version=14.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100061003Microsoft.Office.DocumentManagement, Version=14.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.Docu՜.+,D՜.+,T hp  NeighborCare3e Maryland Board of Pharmacy Titlet4<@Ht     ,Xdp|D _PID_HLINKS_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_PreviousAdHocReviewCycleID_ReviewingToolsShownOnce _dlc_DocId _dlc_DocIdItemGuid _dlc_DocIdUrl 7display_urn:schemas-microsoft-com:office:office#Editor xd_SignatureOrder TemplateUrl xd_ProgID_dlc_DocIdPersistIdPublishingStartDatePublishingExpirationDate7display_urn:schemas-microsoft-com:office:office#Author _SourceUrl_SharedFileIndexContentTypeIdA <x+http://www.dhmh.maryland.gov/p